14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $34.65 $52.95 Wednesday, 28th Feb 2024 CLDX stock ended at $51.37. This is 0.647% more than the trading day before Tuesday, 27th Feb 2024. During the day the stock fluctuated 4.52% from a day low at $50.66 to a day high of $52.95.
90 days $29.34 $52.95
52 weeks $22.11 $52.95

Historical Celldex Therapeutics prices

Date Open High Low Close Volume
2024-02-28 $51.80 $52.95 $50.66 $51.37 991 057
2024-02-27 $49.13 $51.64 $48.81 $51.04 1 880 936
2024-02-26 $39.22 $48.94 $38.96 $48.23 4 756 503
2024-02-23 $37.55 $39.08 $36.60 $37.75 1 181 202
2024-02-22 $38.36 $38.36 $37.08 $37.44 380 646
2024-02-21 $38.36 $39.13 $37.41 $37.72 441 669
2024-02-20 $37.94 $39.09 $37.94 $38.50 576 913
2024-02-16 $36.65 $38.58 $36.18 $38.25 1 180 409
2024-02-15 $36.50 $37.09 $35.65 $36.80 784 406
2024-02-14 $35.85 $36.61 $35.36 $36.26 779 883
2024-02-13 $35.98 $36.09 $35.03 $35.27 532 641
2024-02-12 $38.04 $38.53 $37.56 $37.59 491 800
2024-02-09 $37.75 $38.28 $37.22 $38.04 481 575
2024-02-08 $37.70 $38.01 $37.18 $37.52 450 145
2024-02-07 $37.30 $38.22 $37.30 $37.81 568 880
2024-02-06 $37.39 $38.03 $35.88 $37.20 846 296
2024-02-05 $35.15 $37.25 $35.06 $37.06 698 693
2024-02-02 $35.25 $35.87 $34.65 $35.54 545 631
2024-02-01 $35.35 $36.04 $35.08 $35.50 840 442
2024-01-31 $36.02 $36.41 $35.20 $35.22 637 575
2024-01-30 $36.24 $36.37 $35.60 $36.02 524 527
2024-01-29 $36.31 $36.42 $35.42 $36.38 945 754
2024-01-26 $37.54 $37.78 $36.24 $36.57 398 143
2024-01-25 $38.04 $38.27 $36.93 $37.34 808 812
2024-01-24 $39.10 $39.10 $37.51 $37.53 656 962
Click to get the best stock tips daily for free!

About Celldex Therapeutics

Celldex Therapeutics Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity... CLDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT